Researchers in Moscow have confirmed the effectiveness of telemedicine in managing inflammatory bowel disease (IBD), demonstrating that remote monitoring and online consultations can significantly improve patient outcomes. A recent study found that patients who received care via a specialized telemedicine platform reported lower anxiety levels, better adherence to treatment, and an overall improved quality of life compared to those receiving traditional face-to-face consultations.  Simultaneously, study indicate that remote monitoring is comparable to in-person monitoring in its ability to reduce disease activity and improve quality of life.

In a recent study involving over 60 patients diagnosed with inflammatory bowel diseases, researchers implemented a comparative analysis between two distinct care methods. One group received traditional face-to-face medical consultations, while the other group used a specialized health web platform. This platform enabled patients to report their health status and engage in online consultations with gastroenterologists. The study aimed to evaluate a range of well-being indicators, including quality of life, levels of anxiety and depression, patient satisfaction with medical care, and adherence to prescribed medication regimens. This experiment is a collaborative effort between the Center for Diagnostics and Telemedicine and the I.M. Sechenov First Moscow State Medical University.

The findings revealed a significant reduction in anxiety among the telemedicine group, with levels 30% lower than those in the face-to-face group. Additionally, depression decreased by 29%, and colonic pain sensitivity was reduced by 27%. Notably, both groups experienced a decrease in disease severity.

According to Yuri Vasiliev, CEO of the Center for Diagnostics and Telemedicine of the Moscow Healthcare Department and Chief Consultant for Radiology in the Moscow Healthcare Department, the results clearly demonstrated the benefits of remote care.  

"The results underscore the effectiveness of telemedicine in managing inflammatory bowel diseases," Vasilev noted. "By leveraging digital platforms, patients can access care more conveniently, which may lead to improved psychological outcomes and better adherence to treatment plans."

“IBD patients require continuous treatment and lifelong follow-up. These conditions, including Crohn’s disease and ulcerative colitis, can significantly impact quality of life, making it difficult for patients to visit hospitals regularly. Our research confirms that telemedicine provides a more convenient and accessible alternative, reducing the need for frequent hospital visits while maintaining high standards of care,” said Anton Vladzimirskyy, Dr.Sc. and Deputy Director for Research at the Center for Diagnostics and Telemedicine. 

The study, titled "Effectiveness of Telemedicine in Inflammatory Bowel Diseases in Russia," is a randomized controlled trial. It comprises three stages: (1) patient selection and random assignment into two groups with a 1:1 allocation ratio, (2) follow-up care utilizing either telemonitoring or traditional face-to-face appointments, and (3) evaluation and comparison of the efficacy of follow-up in both groups. This design allows for a comprehensive assessment of telemedicine's impact on managing inflammatory bowel diseases in the Russian healthcare context. The research began in 2023 and is part of Moscow’s broader efforts to integrate telemedicine and artificial intelligence into healthcare. This study adds to a growing body of evidence supporting the role of telemedicine in managing chronic diseases, highlighting its potential to enhance accessibility, improve patient outcomes, and reduce the burden on healthcare systems. 

The Center for Diagnostics and Telemedicine, established in 1996, is a leading scientific and practical organization within the Social Development Complex of the Moscow Mayor's Office. The Center focuses on the implementation of AI in medicine, the advancement of radiology, and the development of medical training programs.